title: [A case of non-curatively resected gastric cancer successfully treated over 3 years with biweekly paclitaxel therapy].
abstract: We report a case of non-curatively resected gastric cancer successfully treated over 3 years with biweekly administration of paclitaxel. A 69-year-old man underwent non-curative resection with distal gastrectomy for advanced gastric cancer with remarkable lymph node metastasis on June 10, 2002. The metastatic lymph node (No. 8 a, 8 p and 12 a) linked up with the retroperitoneal node, making resection impossible. Postoperatively, he was initially treated with weekly administration of paclitaxel 100 mg/body (68 mg/m(2)) per week. However, due to grade 3 neutropenia in the first course, weekly administration was changed to biweekly administration with dose reduction to 60 mg/body (41 mg/m(2)), resulting in the continuation of paclitaxel therapy. Since then, no grade 3 or more severe adverse reactions have been observed. He has maintained NC for 3 years, and is still being treated on an outpatient basis at present. We believe that, in paclitaxel therapy for advanced gastric cancer, it is important for long-term survival to continue it perseveringly by dose reduction or change of schedule, when major adverse reactions are seen.
authors.affiliation: Dept. of Surgery, National Hospital Organization Kobe Medical Center.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yamagishi
authors.forename: Shiro
authors.initials: S
authors.lastname: Kawamura
authors.forename: Mitsuyasu
authors.initials: M
authors.lastname: Tei
authors.forename: Kazuto
authors.initials: K
authors.lastname: Habara
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Sumi
authors.forename: Etsuji
authors.initials: E
authors.lastname: Shimada
authors.forename: Shuichi
authors.initials: S
authors.lastname: Okumura
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005743:Gastrectomy; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017741:Survivors
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel